Capricor Therapeutics (NASDAQ:CAPR) Receives New Coverage from Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a report published on Friday morning, MarketBeat reports. The firm issued an overweight rating and a $8.00 price objective on the biotechnology company’s stock. A number of other equities research analysts have also recently issued reports on CAPR. StockNews.com cut Capricor […]

Related Keywords

,Cantor Fitzgerald ,Cubist Systematic Strategies ,Capricor Therapeutics Company Profile ,Tower Research Capital ,Hightower Advisors ,Renaissance Technologies ,Charles Schwab Investment Management Inc ,Capricor Therapeutics Inc ,Capricor Therapeutics ,Free Report ,Therapeutics Trading Down ,Get Free Report ,Research Capital ,Schwab Investment Management ,Tower Advisors ,Capricor Therapeutics Daily ,Nasdaq Capr ,Capr ,Medical ,Initiated Coverage ,